Intermediate phenotype analysis of patients, unaffected siblings, and healthy controls identifies VMAT2 as a candidate gene for psychotic disorder and neurocognition

Schizophrenia Bulletin

Volumn 39, Issue 4, 2013, Pages 848-856

  Simons, Claudia J P ^a,b   Van Winkel, Ruud ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b GGzE Foundation for Mental Health Care Eindhoven en de Kempen   (Netherlands)

Author keywords

cognition; psychosis; schizophrenia; siblings; single nucleotide polymorphism; vesicular monoamine transporter 2 (VMAT2)

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DNA METHYLTRANSFERASE 3B; FIBROBLAST GROWTH FACTOR 2; MONOAMINE; VESICULAR MONOAMINE TRANSPORTER 2;

ADULT; ARTICLE; CLINICAL ASSESSMENT; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTELLIGENCE QUOTIENT; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; PSYCHOSIS; SIBLING; SINGLE NUCLEOTIDE POLYMORPHISM; SYNAPSE VESICLE; WECHSLER INTELLIGENCE SCALE;

EID: 84879365378     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbs067     Document Type: Article

References (40)

1. Sitskoorn MM, Aleman A, Ebisch SJH, Appels MCM, Kahn RS. Cognitive deficits in relatives of patients with schizophrenia: a meta-analysis. Schizophr Res. 2004; 71: 285-295. (Pubitemid 39330506)
2. Snitz B, MacDonald A, Carter C. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a metaanalytic review of putative endophenotypes. Schizophr Bull. 2006; 32: 179-194. (Pubitemid 43063833)
3. Gur RE, Nimgaonkar VL, Almasy L, et al. Neurocognitive endophenotypes in a multiplex multigenerational family study of schizophrenia. Am J Psychiatry. 2007; 164: 813-819. (Pubitemid 46808537)
4. Plomin R, Craig I. Genetics, environment and cognitive abilities: review and work in progress towards a genome scan for quantitative trait locus associations using DNA pooling. Br J Psychiatry Suppl. 2001; 178: s41-s48. (Pubitemid 32273181)
5. Plomin R, DeFries JC. The genetics of cognitive abilities and disabilities. Sci Am. 1998; 278: 62-69.
6. Toulopoulou T, Picchioni M, Rijsdijk F, et al. Substantial genetic overlap between neurocognition and schizophrenia: genetic modeling in twin samples. Arch Gen Psychiatry. 2007; 64: 1348-1355. (Pubitemid 350223552)
7. Barnett JH, Scoriels L, Munafo MR. Meta-analysis of the cognitive effects of the catechol-O-methyltransferase gene Val158/108Met polymorphism. Biol Psychiatry. 2008; 64: 137-144.
8. Walters JTR, Corvin A, Owen MJ, et al. Psychosis susceptibility gene ZNF804A and cognitive performance in schizophrenia. Arch Gen Psychiatry. 2010; 67: 692-700.
9. Zhang JP, Burdick KE, Lencz T, Malhotra AK. Metaanalysis of genetic variation in DTNBP1 and general cognitive ability. Biol Psychiatry. 2010; 68: 1126-1133.
10. Need AC, Attix DK, McEvoy JM, et al. A genome-wide study of common SNPs and CNVs in cognitive performance in the CANTAB. Hum Mol Genet. 2009; 18: 4650-4661.
11. Purcell SM, Wray NR, Stone JL, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009; 460: 748-752.
12. Wray NR, Visscher PM. Narrowing the boundaries of the genetic architecture of schizophrenia. Schizophr Bull. 2010; 36: 14-23.
13. NIMH.Genetics.Initiative.Family Interview for Genetic Studies (FIGS). Rockville, MD: National Institute of Mental Health; 1992.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, revisied. Washington, DC: American Psychiatric Association; 2000.
15. Andreasen NC, Flaum M, Arndt S. The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry. 1992; 49: 615-623.
16. Wing JK, Babor T, Brugha T, et al. SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry. 1990; 47: 589-593. (Pubitemid 20189971)
17. Genetic Risk and Outcome in Psychosis (GROUP) Investigators. Evidence that familial liability for psychosis is expressed as differential sensitivity to cannabis: an analysis of patientsibling and sibling-control pairs. Arch Gen Psychiatry. 2011; 68: 138-147.
18. Wechsler D. WAIS-III: Wechsler Adult Intelligence Scale. Administration and Scoring Manual. 3rd ed. San Antonio, TX: Psychological Corporation; 1997.
19. Nuechterlein KHR, Dawson ME. Information processing and attentional functioning in the developmental course of schizophrenics disorders. Schizophr Bull. 1984; 10: 160-203.
20. Wohlberg GW, Kornetsky C. Sustained attention in remitted schizophrenics. Arch Gen Psychiatry. 1973; 28: 533-537.
21. Van der Elst W, Boxtel MPJ, Van Breukelen GJP, Jolles J. Rey's verbal learning test: normative data for 1, 855 healthy participants aged 24-81 years and the influence of age, sex, education, and mode of presentation. J Int Neuropsycholog Soc. 2005; 11: 290-302. (Pubitemid 40790621)
22. Bilder RM, Turkel E, Lipschutz-Broch L, Lieberman JA. Antipsychotic medication effects on neuropsychological functions. Psychopharmacol Bull. 1992; 28: 353-366. (Pubitemid 23089722)
23. Nolan KA, Bilder RM, Lachman HM, Volavka J. Catechol O-methyltransferase Val158Met polymorphism in schizophrenia: differential effects of Val and Met alleles on cognitive stability and flexibility. Am J Psychiatry. 2004; 161: 359-361. (Pubitemid 38419288)
24. Meiran N, Levine J, Meiran N, Henik A. Task set switching in schizophrenia. Neuropsychology. 2000; 14: 471-482.
25. Quee PJ, van der Meer L, Bruggeman R, et al. Insight in psychosis: relationship with neurocognition, social cognition and clinical symptoms depends on phase of illness. Schizophr Bull. 2011; 37: 29-37.
26. van Winkel R. Genetic Risk Outcome of Psychosis Investigators. Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch Gen Psychiatry. 2011; 68: 148-157.
27. Cordell HJ, Clayton DG. Genetic association studies. Lancet. 2005; 366: 1121-1131. (Pubitemid 41338767)
28. StataCorp. Stata/SE Statistical Software, Release 11. College Station, TX: StataCorp LP; 2009.
29. Henry J-P, Scherman D. Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles. Biochem Pharmacol. 1989; 38: 2395-2404. (Pubitemid 19188401)
30. Kunugi H, Ishida S, Akahane A, Nanko S. Exon/intron boundaries, novel polymorphisms, and association analysis with schizophrenia of the human synaptic vesicle monoamine transporter (SVMT) gene. Mol Psychiatry. 2001; 6: 456-460. (Pubitemid 32566098)
31. Persico A, Wang Z, Black D, et al. Exclusion of close linkage of the dopamine transporter gene with schizophrenia spectrum disorders. Am J Psychiatry. 1995; 152: 134-136.
32. Gutiérrez B, Rosa A, Papiol S, et al. Identification of two risk haplotypes for schizophrenia and bipolar disorder in the synaptic vesicle monoamine transporter gene (SVMT). Am J Med Genet B Neuropsychiatr Genet. 2007; 144B: 502-507. (Pubitemid 46983162)
33. Zubieta J-K, Taylor SF, Huguelet P, et al. Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects. Biol Psychiatry. 2001; 49: 110-116. (Pubitemid 32119504)
34. Zubieta JK, Huguelet P, Ohl LE, et al. High vesicular monoamine transporter binding in asymptomatic bipolar I disorder: sex differences and cognitive correlates. Am J Psychiatry. 2000; 157: 1619-1628.
35. Talkowski ME, Kirov G, Bamne M, et al. A network of dopaminergic gene variations implicated as risk factors for schizophrenia. Hum Mol Genet. 2008; 17: 747-758. (Pubitemid 351292263)
36. Howes OD, Montgomery AJ, Asselin M-C, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry. 2009; 66: 13-20.
37. O'Daly OG, Joyce D, Stephan KE, Murray RM, Shergill SS. Functional magnetic resonance imaging investigation of the amphetamine sensitization model of schizophrenia in healthy male volunteers. Arch Gen Psychiatry. 2011; 68: 545-554.
38. Taylor SF, Koeppe RA, Tandon R, Zubieta JK, Frey KA. In vivo measurement of the vesicular monoamine transporter in schizophrenia. Neuropsychopharmacology. 2000; 23: 667-675.
39. Collins AL, Kim Y, Sklar P, O'Donovan MC, Sullivan PF. Hypothesis-driven candidate genes for schizophrenia compared to genome-wide association results. Psychol Med. 2012; 42: 607-616.
40. Cirillo MA, Seidman LJ. Verbal declarative memory dysfunction in schizophrenia: from clinical assessment to genetics and brain mechanisms. Neuropsychol Rev. 2003; 13: 43-77. (Pubitemid 38113372)